Search research articles
Contact Us
Filters
Showing results (231-240 of 271) with videos related to
Page
of 28
Sort By:
JAMA Network Open
|
June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders
Kylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Teresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
The New England Journal of Medicine
|
November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutation
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 24, 2025
International survey on training of dermatology residents in supportive oncodermatology: the RESCUE study
Ariadna Ortiz-Brugués, Davide Fattore, Marie Boileau, et al.
The Lancet. Oncology
|
March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Cancers
|
February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 271) with videos related to
Sort By:
Page
of 28
JAMA Network Open
|
June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders
Kylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Teresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
The New England Journal of Medicine
|
November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutation
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 24, 2025
International survey on training of dermatology residents in supportive oncodermatology: the RESCUE study
Ariadna Ortiz-Brugués, Davide Fattore, Marie Boileau, et al.
The Lancet. Oncology
|
March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Cancers
|
February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Page
of 28